CML-话题@MedSci

#CML#

32篇内容 | 2372人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2257713, encodeId=e7ad225e7135c, content=<a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=【JAMA】综述：慢性髓性白血病, objectType=article, longId=868823, objectId=a82c868823b9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250219/1739954389280_8538692.jpg, objectUrl=/article/show_article.do?id=a82c868823b9, replyNumber=0, likeNumber=8, createdTime=2025-03-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=a82c868823b9, moduleTitle=【JAMA】综述：慢性髓性白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a82c868823b9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2250533, encodeId=680c225053384, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a> <a href='/topic/show?id=889661826fb' target=_blank style='color:#2F92EE;'>#染色体异常#</a>, objectTitle=【AJH】CML附加染色体异常的临床和预后意义, objectType=article, longId=861930, objectId=6a0a861930cc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220801/1659324313353_8252897.webp, objectUrl=/article/show_article.do?id=6a0a861930cc, replyNumber=0, likeNumber=14, createdTime=2025-02-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=6a0a861930cc, moduleTitle=【AJH】CML附加染色体异常的临床和预后意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a0a861930cc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2219307, encodeId=a5be221930e95, content=<a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=【AJH】慢性髓性白血病的诊断、治疗和监测（2025更新）, objectType=article, longId=838140, objectId=905e8381402a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240808/1723100817260_8538692.jpg, objectUrl=/article/show_article.do?id=905e8381402a, replyNumber=0, likeNumber=61, createdTime=2024-08-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=905e8381402a, moduleTitle=【AJH】慢性髓性白血病的诊断、治疗和监测（2025更新）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=905e8381402a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2213790, encodeId=2bd52213e9086, content=<a href='/topic/show?id=69da53614b0' target=_blank style='color:#2F92EE;'>#慢性粒细胞白血病#</a> <a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a> <a href='/topic/show?id=801f63948b2' target=_blank style='color:#2F92EE;'>#氟马替尼#</a>, objectTitle=【Haematologica】氟马替尼治疗2线-4线CML的多中心回顾性研究, objectType=article, longId=833476, objectId=3c258334e60f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240707/1720361749611_5579292.jpg, objectUrl=/article/show_article.do?id=3c258334e60f, replyNumber=0, likeNumber=117, createdTime=2024-07-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3c258334e60f, moduleTitle=【Haematologica】氟马替尼治疗2线-4线CML的多中心回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c258334e60f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2209286, encodeId=eeba220928616, content=<a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a> <a href='/topic/show?id=5c302825aa' target=_blank style='color:#2F92EE;'>#Asciminib#</a>, objectTitle=STAMP抑制剂Asciminib治疗初治CML的3期研究结果, objectType=article, longId=829565, objectId=4d648295652b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240610/1718034049198_5579292.jpg, objectUrl=/article/show_article.do?id=4d648295652b, replyNumber=0, likeNumber=71, createdTime=2024-06-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4d648295652b, moduleTitle=STAMP抑制剂Asciminib治疗初治CML的3期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d648295652b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2205416, encodeId=97bd2205416ec, content=<a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a> <a href='/topic/show?id=a3e111460352' target=_blank style='color:#2F92EE;'>#费城染色体变异#</a>, objectTitle=【AJH】CML存在附加染色体异常或费城染色体变异易位不影响无治疗缓解率, objectType=article, longId=826394, objectId=1b0882639451, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240518/1716030679051_5579292.jpg, objectUrl=/article/show_article.do?id=1b0882639451, replyNumber=0, likeNumber=97, createdTime=2024-05-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1b0882639451, moduleTitle=【AJH】CML存在附加染色体异常或费城染色体变异易位不影响无治疗缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b0882639451)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2199165, encodeId=896f2199165dd, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a> <a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=【Blood Reviews】慢性髓性白血病综述：从生物学到治疗, objectType=article, longId=821943, objectId=5713821943f3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/filling-medical-history-XZB9RVX.jpg, objectUrl=/article/show_article.do?id=5713821943f3, replyNumber=0, likeNumber=97, createdTime=2024-04-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=5713821943f3, moduleTitle=【Blood Reviews】慢性髓性白血病综述：从生物学到治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5713821943f3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2197487, encodeId=b3ea219e487e8, content=<a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a> <a href='/topic/show?id=70121e506e2' target=_blank style='color:#2F92EE;'>#TKI治疗#</a>, objectTitle=【Leukemia】TKI时代急变期CML的治疗模式和结局, objectType=article, longId=820699, objectId=1947820699f1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/busy-reception-in-a-hospital-with-doctors-and-PUPDEB8.jpg, objectUrl=/article/show_article.do?id=1947820699f1, replyNumber=0, likeNumber=87, createdTime=2024-04-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=1947820699f1, moduleTitle=【Leukemia】TKI时代急变期CML的治疗模式和结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1947820699f1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188905, encodeId=a0dc218890518, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a> <a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=【BJH】慢性期CML患者停用TKI后分子学复发的动力学（附专家点评）, objectType=article, longId=814228, objectId=a49081422881, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-filling-form-U2MAYRK.jpg, objectUrl=/article/show_article.do?id=a49081422881, replyNumber=0, likeNumber=94, createdTime=2024-02-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a49081422881, moduleTitle=【BJH】慢性期CML患者停用TKI后分子学复发的动力学（附专家点评）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a49081422881)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1488720, encodeId=f1ea1488e209a, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=武田制药将呈报ICLUSIG® (ponatinib) 2期OPTIC试验主要分析的阳性结果，加强填补慢性期CML治疗空白的能力, objectType=article, longId=211778, objectId=aba2211e7815, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aba2211e7815, replyNumber=0, likeNumber=113, createdTime=2021-05-26, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aba2211e7815, moduleTitle=武田制药将呈报ICLUSIG® (ponatinib) 2期OPTIC试验主要分析的阳性结果，加强填补慢性期CML治疗空白的能力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aba2211e7815)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488719, encodeId=7a9b1488e1901, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=美国FDA核准武田ICLUSIG® (ponatinib)用于耐药或不耐受慢性期CML成人患者的补充新药申请, objectType=article, longId=204831, objectId=316c204831cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=316c204831cf, replyNumber=0, likeNumber=76, createdTime=2020-12-25, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=316c204831cf, moduleTitle=美国FDA核准武田ICLUSIG® (ponatinib)用于耐药或不耐受慢性期CML成人患者的补充新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=316c204831cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488718, encodeId=18641488e1891, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=CLIN CHEM LAB MED：拉丁美洲CML患者BCR-ABL1量化方案？, objectType=article, longId=203922, objectId=2da2203922c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2da2203922c1, replyNumber=0, likeNumber=74, createdTime=2020-12-02, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2da2203922c1, moduleTitle=CLIN CHEM LAB MED：拉丁美洲CML患者BCR-ABL1量化方案？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2da2203922c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488717, encodeId=7f6e1488e175b, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=Blood：BCR-ABL1早期动力学可预测CML无治疗缓解的长期预后, objectType=article, longId=200652, objectId=9d89200652e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d89200652e5, replyNumber=0, likeNumber=91, createdTime=2020-09-15, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d89200652e5, moduleTitle=Blood：BCR-ABL1早期动力学可预测CML无治疗缓解的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d89200652e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488716, encodeId=037a1488e16cf, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=Blood：miR-185/PAK6轴调控CML耐药性白血病干细胞的存活，可预测治疗反应性, objectType=article, longId=192492, objectId=9f3f19249258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f3f19249258, replyNumber=0, likeNumber=95, createdTime=2020-04-20, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f3f19249258, moduleTitle=Blood：miR-185/PAK6轴调控CML耐药性白血病干细胞的存活，可预测治疗反应性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f3f19249258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488715, encodeId=4a3c1488e1533, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=J Clin Oncol：鲁索替尼治疗有无CSF3R突变的CNL或aCML患者的疗效和安全性, objectType=article, longId=185703, objectId=5b57185e0330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b57185e0330, replyNumber=0, likeNumber=95, createdTime=2020-01-06, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b57185e0330, moduleTitle=J Clin Oncol：鲁索替尼治疗有无CSF3R突变的CNL或aCML患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b57185e0330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488714, encodeId=49d71488e1422, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=Blood：KLF4-DYRK2介导通路调节CML干细胞的自我更新, objectType=article, longId=185589, objectId=8f2d1855898d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f2d1855898d, replyNumber=0, likeNumber=68, createdTime=2020-01-04, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f2d1855898d, moduleTitle=Blood：KLF4-DYRK2介导通路调节CML干细胞的自我更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f2d1855898d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488713, encodeId=2aa61488e1387, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=Blood：DYRK2，CML的新潜在治疗靶点！, objectType=article, longId=179601, objectId=04f51e960152, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04f51e960152, replyNumber=0, likeNumber=83, createdTime=2019-09-18, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04f51e960152, moduleTitle=Blood：DYRK2，CML的新潜在治疗靶点！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04f51e960152)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488712, encodeId=416c1488e1215, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=Blood：尼洛替尼替代伊马替尼治疗Ph+CML-CP儿童患者, objectType=article, longId=179592, objectId=dc5f1e95921f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc5f1e95921f, replyNumber=0, likeNumber=89, createdTime=2019-09-18, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc5f1e95921f, moduleTitle=Blood：尼洛替尼替代伊马替尼治疗Ph+CML-CP儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc5f1e95921f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488711, encodeId=72bf1488e11c0, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=国产伊马替尼治疗CML延长追踪疗效确切, objectType=article, longId=168854, objectId=b997168854c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b997168854c2, replyNumber=0, likeNumber=108, createdTime=2019-06-22, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b997168854c2, moduleTitle=国产伊马替尼治疗CML延长追踪疗效确切, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b997168854c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488710, encodeId=7a5f1488e1064, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=氟马替尼治疗CML-CP的疗效与安全性解读, objectType=article, longId=167915, objectId=68f016e91570, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68f016e91570, replyNumber=0, likeNumber=96, createdTime=2019-06-11, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68f016e91570, moduleTitle=氟马替尼治疗CML-CP的疗效与安全性解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68f016e91570)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CML

2020-05-29

梅斯管理员

#慢性髓性白血病# #CML#

【JAMA】综述：慢性髓性白血病

2025-03-25发表于陕西省

梅斯管理员

#CML# #染色体异常#

【AJH】CML附加染色体异常的临床和预后意义

2025-02-05发表于陕西省

梅斯管理员

#慢性髓性白血病# #CML#

【AJH】慢性髓性白血病的诊断、治疗和监测（2025更新）

2024-08-09发表于上海

梅斯管理员

#慢性粒细胞白血病# #CML# #氟马替尼#

【Haematologica】氟马替尼治疗2线-4线CML的多中心回顾性研究

2024-07-07发表于上海

梅斯管理员

#慢性髓性白血病# #CML# #Asciminib#

STAMP抑制剂Asciminib治疗初治CML的3期研究结果

2024-06-10发表于上海

梅斯管理员

#慢性髓性白血病# #CML# #费城染色体变异#

【AJH】CML存在附加染色体异常或费城染色体变异易位不影响无治疗缓解率

2024-05-18发表于上海

梅斯管理员

#TKI# #慢性髓性白血病# #CML#

【Blood Reviews】慢性髓性白血病综述：从生物学到治疗

2024-04-18发表于陕西省

梅斯管理员

#慢性髓性白血病# #CML# #TKI治疗#

【Leukemia】TKI时代急变期CML的治疗模式和结局

2024-04-08发表于陕西省

梅斯管理员

#TKI# #慢性髓性白血病# #CML#

【BJH】慢性期CML患者停用TKI后分子学复发的动力学（附专家点评）

2024-02-23发表于上海

wangbingxhy

#CML#

武田制药将呈报ICLUSIG® (ponatinib) 2期OPTIC试验主要分析的阳性结果，加强填补慢性期CML治疗空白的能力

2021-05-26

wangbingxhy

#CML#

美国FDA核准武田ICLUSIG® (ponatinib)用于耐药或不耐受慢性期CML成人患者的补充新药申请

2020-12-25

wangbingxhy

#CML#

CLIN CHEM LAB MED：拉丁美洲CML患者BCR-ABL1量化方案？

2020-12-02

wangbingxhy

#CML#

Blood：BCR-ABL1早期动力学可预测CML无治疗缓解的长期预后

2020-09-15

wangbingxhy

#CML#

Blood：miR-185/PAK6轴调控CML耐药性白血病干细胞的存活，可预测治疗反应性

2020-04-20

wangbingxhy

#CML#

J Clin Oncol：鲁索替尼治疗有无CSF3R突变的CNL或aCML患者的疗效和安全性

2020-01-06

wangbingxhy

#CML#

Blood：KLF4-DYRK2介导通路调节CML干细胞的自我更新

2020-01-04

wangbingxhy

#CML#

Blood：DYRK2，CML的新潜在治疗靶点！

2019-09-18

wangbingxhy

#CML#

Blood：尼洛替尼替代伊马替尼治疗Ph+CML-CP儿童患者

2019-09-18

wangbingxhy

#CML#

国产伊马替尼治疗CML延长追踪疗效确切

2019-06-22

wangbingxhy

#CML#

氟马替尼治疗CML-CP的疗效与安全性解读

2019-06-11